Update on the "engineered antibody" approach being pursued by Regeneron and other companies - they don't all do it the same way, but they all produce some sort of antibody "cocktail" to boost the ability of the body to neutralize the cell invasion/replication of the virus. This antibody cocktail can be infused into humans as a treatment for those ill with the virus or as a somewhat short term prophylactic for healthy people until a longer acting vaccine is available.
As per the quoted post, Regeneron used this approach with significant success in treating patients sick with the Ebola virus, so the approach should work. How well and for how long are the big questions. Regeneron has seen success in the lab and has selected their cocktail of antibodies to test in monkeys shortly, with potential human clinical trials to start in late June.
If successful, commercial launch would come in August with the potential to treat 20K sick patients per month or 200K healthy at-risk patients (more is needed for sick patients) - ramping up to millions should only take a few months. There are several other companies working in this area, too, with similar timelines. Crossing fingers, especially since if this or the convalescent plasma-antibody treatment in ongoing trials now is highly effective for seriously ill patients, it's a gamechanger, as it would give most people confidence to return to "somewhat normal" life (especially young/healthy people).
“The odds are very high this will work, especially when you have multiple programs and multiple manufacturers,” says James Crowe, a veteran immunologist at Vanderbilt University Medical Center who’s working with AstraZeneca Plc and others on Covid-19 treatments. Scott Gottlieb, former head of the U.S. Food and Drug Administration, also sounded optimistic in a recent interview with Bloomberg News, saying, “If I had to place one bet on a drug that could be available by the summer and could have activity and could have a profile that I think could change the contours of the infection, it would be the antibody approaches.”
https://www.bloomberg.com/news/feat...JqQM4w5jnsXJpRhOUKFQlLBQMbRF5kX3TztXuDw09IloU